Sujata Bhoi
Huddinge, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
A phase Ib/2a study of fostrox in combination with lenvatinib as second line therapy in patients with advanced hepatocellular carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 23, 2026
A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 23, 2026
A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases.
Journal: Journal of hepatocellular carcinoma
Published: June 06, 2024
DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy.
Journal: Clinical epigenetics
Published: September 24, 2019
Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia.
Journal: International journal of cancer
Published: March 06, 2018
UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?
Journal: Haematologica
Published: November 22, 2015
Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia.
Journal: The Journal of experimental medicine
Published: October 23, 2014
Histidine-rich glycoprotein uptake and turnover is mediated by mononuclear phagocytes.
Journal: PloS one
Published: April 07, 2014
Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?
Journal: Leukemia & lymphoma
Published: March 14, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026